Economic evaluation demonstrates that moxifloxacin IV/PO monotherapy is cost-effective to the Spanish National Healthcare System when compared to IV/PO amoxicillin/clavulanate +/- clarithromycin in the treatment of community-acquired pneumonia

M Drummond, D Becker, M Hux, J Chancellor, I Duprat-Lomon, P P Sagnier

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)565-565
Number of pages1
JournalValue in Health
Issue number6
Publication statusPublished - 2002

Cite this